Background: Initial Call for Views and UK Government Response

Earlier this year DLA Piper reported on the UK government’s response to its consultation on AI and potential amendments to existing intellectual property law. The initial call for views sought to gain insight into how individuals and organisations believe that AI
Continue Reading UK consultation on treatment of AI in copyright and patents legislation

By Michal Kasprowicz and Sangeetha Punniyamoorthy

Due to the coronavirus disease 2019 (COVID-19) pandemic there have been recent amendments to Canada’s Patent Act that will authorize the use of certain patented inventions necessary to respond in a public health emergency. These measures will authorize the manufacturing and distribution of patented
Continue Reading COVID-19’s Impact on Canadian patent owners

Trial and error – with the vast majority of trials ending in error – has long been the default method of drug discovery. Of the USD2.6 billion spent each year on drug discovery by the world’s largest pharmaceutical companies, at least nine-tenths will go toward funding drug research that will
Continue Reading The error of trials: Legal considerations when deploying AI in drug development